<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00030108</url>
  </required_header>
  <id_info>
    <org_study_id>020031</org_study_id>
    <secondary_id>02-C-0031</secondary_id>
    <secondary_id>NCI-5425</secondary_id>
    <secondary_id>CDR0000069133</secondary_id>
    <nct_id>NCT00030108</nct_id>
    <nct_alias>NCT00025961</nct_alias>
  </id_info>
  <brief_title>Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy</brief_title>
  <official_title>Phase I Trial and Pharmacokinetic Study of BMS-247550 (NSC 710428, Ixabepilone), an Epothilone B Analog, in Pediatric Patients With Refractory Solid Tumors and Leukemias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institutes of Health Clinical Center (CC)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of ixabepilone in&#xD;
      treating young patients with relapsed or refractory solid tumors or leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT) of&#xD;
           ixabepilone in young patients with refractory solid tumors (closed to accrual as of&#xD;
           10/4/2007) or relapsed or refractory leukemia.&#xD;
&#xD;
        -  Determine the toxicity spectrum of this drug in these patients.&#xD;
&#xD;
        -  Determine the plasma pharmacokinetics of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacodynamics of this drug in these patients.&#xD;
&#xD;
        -  Assess the nerve growth factor levels, before and after the initiation of this drug, as&#xD;
           a potential surrogate marker for the development of peripheral neuropathy in these&#xD;
           patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the response of patients treated with this drug.&#xD;
&#xD;
        -  Compare the tolerability, toxicity profile, MTD, DLT, pharmacokinetics, and&#xD;
           pharmacodynamics of this drug in young patients treated on this study vs adults with&#xD;
           solid tumors (closed to accrual as of 10/4/2007) treated on the ongoing Medicine Branch,&#xD;
           NCI, phase I study.&#xD;
&#xD;
        -  Assess the safety and tolerability of ixabepilone at the solid tumor MTD (expanded&#xD;
           leukemia cohort).&#xD;
&#xD;
        -  Evaluate the plasma pharmacokinetics of in young patients with refractory or relapsed&#xD;
           leukemia.&#xD;
&#xD;
        -  Evaluate the extent of tubulin polymerization in leukemic blasts at baseline after&#xD;
           treatment with ixabepilone ex-vivo.&#xD;
&#xD;
        -  Compare the effects of tubulin polymerization in leukemic blasts with ixabepilone versus&#xD;
           paclitaxel ex-vivo with an without the presence of a potent P-glycoprotein inhibitor.&#xD;
&#xD;
        -  Evaluate the activity known drug transporters in drug-resistant leukemias in leukemic&#xD;
           blasts.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study.&#xD;
&#xD;
      Patients receive ixabepilone IV over 1 hour on days 1-5. Treatment repeats every 21 days in&#xD;
      the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of ixabepilone until the maximum tolerated&#xD;
      dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 or more of&#xD;
      6 patients experience dose-limiting toxicity. Intrapatient dose escalation to one dose level&#xD;
      above the enrollment dose level is allowed in patients who have stable or responding disease&#xD;
      or are experiencing other benefits from therapy (e.g., decrease in tumor-related pain&#xD;
      symptoms) and who have no grade 2 or greater non-hematologic toxicity and no grade 3 or&#xD;
      greater hematologic toxicity. Additional patients are treated at the MTD. Patients treated at&#xD;
      the MTD may not undergo intrapatient dose escalation.&#xD;
&#xD;
      PROJECTED ACCRUAL: A maximum of 30 patients will be accrued for this study within 1-2 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">March 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose and dose-limiting toxicity of ixabepilone</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Toxicity spectrum</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma pharmacokinetics</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamics</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Nerve growth factor levels before and after drug administration</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective tumor response</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tubulin polymerization in PBMCs prior to the start of the infusion, just before the end of the infusion, 5 hours after the end of the infusion and before the start of the infusion on day 2 of the ixabepilone on course 1</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <condition>Childhood Germ Cell Tumor</condition>
  <condition>Extragonadal Germ Cell Tumor</condition>
  <condition>Kidney Cancer</condition>
  <condition>Leukemia</condition>
  <condition>Liver Cancer</condition>
  <condition>Neuroblastoma</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Sarcoma</condition>
  <condition>Unspecified Childhood Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ixabepilone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Meets 1 of the following criteria:&#xD;
&#xD;
               -  Histologically confirmed solid tumor (closed to accrual as of 10/4/2007) that&#xD;
                  relapsed after or failed to respond to front-line curative therapy and for which&#xD;
                  no other potentially curative treatment options exist&#xD;
&#xD;
                    -  Curative therapy may include surgery, radiotherapy, chemotherapy, or any&#xD;
                       combination of these modalities&#xD;
&#xD;
                    -  Eligible tumor types include, but are not limited to, the following:&#xD;
&#xD;
                         -  Rhabdomyosarcoma&#xD;
&#xD;
                         -  Other soft tissue sarcomas&#xD;
&#xD;
                         -  Ewing's sarcoma family of tumors&#xD;
&#xD;
                         -  Osteosarcoma&#xD;
&#xD;
                         -  Neuroblastoma&#xD;
&#xD;
                         -  Wilms' tumor&#xD;
&#xD;
                         -  Hepatic tumors&#xD;
&#xD;
                         -  Germ cell tumors&#xD;
&#xD;
                         -  Primary brain tumors&#xD;
&#xD;
                              -  Histologic confirmation may be waived for brain stem or optic&#xD;
                                 glioma&#xD;
&#xD;
               -  Diagnosis of relapsed or refractory leukemia&#xD;
&#xD;
                    -  Patients with refractory or second or greater relapsed leukemia must have &gt;&#xD;
                       25% blasts in the bone marrow (M3 bone marrow) with or without active&#xD;
                       extramedullary disease (except for leptomeningeal disease)&#xD;
&#xD;
                    -  Relapsed after or failed to respond to frontline curative therapy and no&#xD;
                       other potentially curative therapy (e.g., radiotherapy, chemotherapy, or any&#xD;
                       combination of these modalities) exists&#xD;
&#xD;
               -  Patients with acute promyelocytic leukemia must be refractory to treatment with&#xD;
                  retinoic acid and arsenic trioxide&#xD;
&#xD;
               -  Patients with Philadelphia chromosome positive chronic myelogenous leukemia must&#xD;
                  be refractory to imatinib&#xD;
&#xD;
          -  No active CNS leukemia (CNS3)&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  2 to 18 (solid tumor patients [closed to accrual as of 10/4/2007])&#xD;
&#xD;
          -  1 to 21 (leukemia patients)&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  For patients age 11 to 21:&#xD;
&#xD;
               -  Karnofsky 50-100%&#xD;
&#xD;
          -  For patients age 1 to 10:&#xD;
&#xD;
               -  Lansky 50-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3 (20,000/mm^3 for leukemia patients)&#xD;
&#xD;
          -  Hemoglobin ≥ 8.0 g/dL&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  SGOT and SGPT less than 2.5 times ULN&#xD;
&#xD;
          -  No hepatic dysfunction that would preclude study&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine normal for age OR&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No renal dysfunction that would preclude study&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No known severe prior hypersensitivity reaction to agents containing Cremophor EL&#xD;
&#xD;
          -  No clinically significant unrelated systemic illness (e.g., serious infections or&#xD;
             other organ dysfunction) that would preclude study&#xD;
&#xD;
          -  No grade 2 or greater preexisting sensory neuropathy&#xD;
&#xD;
          -  More than 2 month since prior and no concurrent evidence of graft vs host disease&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  Recovered from all therapy-related acute toxic effects (leukemia patients only)&#xD;
&#xD;
          -  Prior epoetin alfa allowed&#xD;
&#xD;
          -  At least 3 days since other prior colony-stimulating factors (e.g., filgrastim&#xD;
             (G-CSF), sargramostim (GM-CSF), or interleukin-11 (IL-11))&#xD;
&#xD;
          -  At least 6 months since prior bone marrow transplantation&#xD;
&#xD;
          -  At least 2 months since prior stem cell transplantation or rescue (leukemia patients)&#xD;
&#xD;
          -  At least 7 days since prior therapy with a biological agent and hematopoietic growth&#xD;
             factor with the exception of erythropoietin&#xD;
&#xD;
          -  More than 3 weeks since prior monoclonal antibody therapy (leukemia patients only)&#xD;
&#xD;
          -  No concurrent GM-CSF or IL-11&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from all therapy-related acute toxic effects (leukemia patients only)&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas)&#xD;
&#xD;
          -  No other concurrent anticancer chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Concurrent corticosteroids allowed for the control of symptoms related to&#xD;
             tumor-associated edema in patients with brain tumors&#xD;
&#xD;
          -  Patients with brain tumors must be on a stable or tapering dose of corticosteroids for&#xD;
             7 days before baseline scan is performed for the purpose of assessing response to&#xD;
             study therapy&#xD;
&#xD;
          -  Must be on a stable or tapering dose of corticosteroids for 7 days prior to study&#xD;
             entry (leukemia patients only)&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  Recovered from all therapy-related acute toxic effects (leukemia patients only)&#xD;
&#xD;
          -  At least 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  More than 2 weeks since prior local palliative radiotherapy (leukemia patients only)&#xD;
&#xD;
          -  More than 3 months since prior total-body irradiation, craniospinal radiotherapy, or&#xD;
             radiotherapy to ≥50% of the pelvis (leukemia patients only)&#xD;
&#xD;
          -  More than 6 weeks since prior other substantial bone marrow radiotherapy (leukemia&#xD;
             patients only)&#xD;
&#xD;
          -  No prior extensive radiotherapy (e.g., craniospinal irradiation, total body&#xD;
             irradiation, or radiotherapy to more than half of the pelvis)&#xD;
&#xD;
          -  No concurrent anticancer radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Recovered from prior therapy&#xD;
&#xD;
          -  At least 30 days since any prior investigational anticancer therapy&#xD;
&#xD;
          -  At least 1 week since prior known inhibitors of CYP3A4, including any of the&#xD;
             following:&#xD;
&#xD;
               -  Antibiotics (i.e., clarithromycin, erythromycin, or troleandomycin)&#xD;
&#xD;
               -  Anti-HIV agents (i.e, delaviridine, nelfinavir, amprenavir, ritonavir, idinavir,&#xD;
                  saquinavir, or lopinavir)&#xD;
&#xD;
               -  Anti-fungals (i.e., itraconazole, ketoconazole, fluconazole [doses &gt; 3mg/kg/day],&#xD;
                  or voriconazole)&#xD;
&#xD;
               -  Anti-depressants (i.e., nefaxodone or fluovoxamine)&#xD;
&#xD;
               -  Calcium channel blockers (i.e., verapamil or diltiazem)&#xD;
&#xD;
               -  Anti-emetics (i.e., aprepitant [Emend®])&#xD;
&#xD;
               -  Miscellaneous agents (i.e., amiodarone)&#xD;
&#xD;
               -  Grapefruit juice&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No concurrent St. John's Wort&#xD;
&#xD;
          -  No concurrent known inhibitors of CYP3A4, including grapefruit juice&#xD;
&#xD;
          -  Concurrent other agents inducing CYP3A4 allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AeRang Kim, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's National Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20010-2970</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Widemann BC, Goodspeed W, Goodwin A, Fojo T, Balis FM, Fox E. Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors. J Clin Oncol. 2009 Feb 1;27(4):550-6. doi: 10.1200/JCO.2008.17.6644. Epub 2008 Dec 15.</citation>
    <PMID>19075272</PMID>
  </results_reference>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>January 30, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>March 14, 2012</last_update_submitted>
  <last_update_submitted_qc>March 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2012</last_update_posted>
  <keyword>recurrent childhood rhabdomyosarcoma</keyword>
  <keyword>childhood craniopharyngioma</keyword>
  <keyword>recurrent neuroblastoma</keyword>
  <keyword>recurrent childhood liver cancer</keyword>
  <keyword>recurrent Wilms tumor and other childhood kidney tumors</keyword>
  <keyword>childhood central nervous system germ cell tumor</keyword>
  <keyword>recurrent osteosarcoma</keyword>
  <keyword>unspecified childhood solid tumor, protocol specific</keyword>
  <keyword>childhood germ cell tumor</keyword>
  <keyword>recurrent childhood soft tissue sarcoma</keyword>
  <keyword>childhood oligodendroglioma</keyword>
  <keyword>childhood choroid plexus tumor</keyword>
  <keyword>childhood grade I meningioma</keyword>
  <keyword>childhood grade II meningioma</keyword>
  <keyword>childhood grade III meningioma</keyword>
  <keyword>recurrent childhood cerebellar astrocytoma</keyword>
  <keyword>recurrent childhood cerebral astrocytoma</keyword>
  <keyword>recurrent childhood medulloblastoma</keyword>
  <keyword>recurrent childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>previously treated childhood rhabdomyosarcoma</keyword>
  <keyword>recurrent Ewing sarcoma/peripheral primitive neuroectodermal tumor</keyword>
  <keyword>recurrent childhood ependymoma</keyword>
  <keyword>childhood teratoma</keyword>
  <keyword>childhood malignant testicular germ cell tumor</keyword>
  <keyword>childhood malignant ovarian germ cell tumor</keyword>
  <keyword>childhood extragonadal germ cell tumor</keyword>
  <keyword>recurrent childhood malignant germ cell tumor</keyword>
  <keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
  <keyword>childhood acute basophilic leukemia</keyword>
  <keyword>childhood acute eosinophilic leukemia</keyword>
  <keyword>childhood acute lymphoblastic leukemia</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>childhood acute promyelocytic leukemia (M3)</keyword>
  <keyword>L1 childhood acute lymphoblastic leukemia</keyword>
  <keyword>L2 childhood acute lymphoblastic leukemia</keyword>
  <keyword>L3 childhood acute lymphoblastic leukemia</keyword>
  <keyword>non-T, non-B, cALLa negative childhood acute lymphoblastic leukemia</keyword>
  <keyword>non-T, non-B, cALLa positive childhood acute lymphoblastic leukemia</keyword>
  <keyword>non-T, non-B, cALLa positive, pre-B childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>TdT negative childhood acute lymphoblastic leukemia</keyword>
  <keyword>TdT positive childhood acute lymphoblastic leukemia</keyword>
  <keyword>chronic myelogenous leukemia, BCR-ABL1 positive</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

